Diabetes drug shows promise in fighting Alzheimer's brain inflammation

NCT ID NCT05891496

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

Summary

This study tested whether semaglutide, a medication used for diabetes and weight loss, could help reduce inflammation in the brains of people with Alzheimer's disease. For 12 weeks, 23 participants with mild Alzheimer's symptoms received either the real medication or a placebo injection, followed by 52 weeks where everyone received the medication. Researchers measured changes in brain and blood inflammation markers to see if the drug could be repurposed for Alzheimer's treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Azienda Ospedaliera Spedali Civili di Brescia

Brescia, 25123, Italy
Azienda Ospedaliera di Perugia;Ospedale S. Maria della Miser

Perugia, 06132, Italy
Banner Sun Health Research Institute

Sun City, Arizona, 85351, United States
Brain Matters Research

Delray Beach, Florida, 33445, United States
Centre de la Mémoire

Geneva, 1205, Switzerland
Fondazione Santa Lucia IRCCS

Roma, 00179, Italy
Karolinska Universitetssjukhuset, Huddinge

Stockholm, 141 86, Sweden
Memory Program

Toronto, Ontario, M3B2S7, Canada
Ottawa Memory Clinic

Ottawa, Ontario, K1Z 1G3, Canada
Rigshospitalet - afsnit 8015

København Ø, 2100, Denmark
Rigshospitalet - afsnit 8015 Hukommelsesklinikken

København Ø, 2100, Denmark

Conditions

Explore the condition pages connected to this study.

ALZHEIMERS DISEASE